Rituximab for the treatment of acquired antibodies to factor VIII
Background and Objectives Rituximab, a monoclonal chimeric antibody to the CD20 antigen, is an effective therapy for the treatment of non-Hodgkin’s lymphomas. Moreover, rituximab has also shown to be effective in various autoimmune diseases including spontaneous antibodies to factor VIII. The aim of...
-д хадгалсан:
| Үндсэн зохиолчид: | , , |
|---|---|
| Формат: | Artigo |
| Хэл сонгох: | Inglês |
| Хэвлэсэн: |
Ferrata Storti Foundation
2007-01-01
|
| Цуврал: | Haematologica |
| Онлайн хандалт: | https://haematologica.org/article/view/4307 |
| Шошгууд: |
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|